Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and womenâ€™s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimuneâ€™s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.0138 $	+6.15%	1,124,597,953
26-06-11	0.0130 $	-29.73%	656,191,691
26-06-10	0.0185 $	-35.99%	244,949,839
26-06-09	0.0289 $	-42.08%	399,131,771
26-06-08	0.0499 $	-19.65%	37,119,522

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 15:09:51 2026-06-12 EDT			5-day change	1st Jan Change
0.0138 ^USD	+6.15%		-77.78%	-99.99%

07:15am	Top Premarket Gainers	MT
06-10	Top Premarket Decliners	MT

07:15am	Top Premarket Gainers	MT
06-10	Top Premarket Decliners	MT
06-09	Aditxt's Ignite Proteomics Unit to Go Public in $150 Million Deal	MT
06-05	Aditxt, Inc. Announces Board and Executive Changes, Effective June 2, 2026	CI
06-02	Aditxt, Inc. announced that it expects to receive $0.47125 million in funding	CI
06-01	Aditxt Names Jeffrey Busch as Interim CEO	MT
06-01	Aditxt, Inc. Announces CEO Changes	CI
06-01	Aditxt, Inc. Announces Management Changes	CI
06-01	Aditxt appoints Jeffrey M. Busch as interim CEO; founder and former CEO of $1B NYSE enterprise which delivered ~8.5% dividends to Shareholders	RE
06-01	Top Premarket Decliners	MT
05-27	Aditxt, Inc.(NasdaqCM:ADTX) added to NASDAQ Composite Index	CI
05-27	Top Premarket Decliners	MT
05-26	Aditxt, Inc.(NasdaqCM:ADTX) dropped from NASDAQ Composite Index	CI

22-11-14	HC Wainwright Starts Aditxt at Buy With $4 Price Target	MT
22-09-16	Dawson James Downgrades Aditxt to Neutral from Buy	MT
22-09-16	Dawson James Downgrades Aditxt to Neutral From Buy	MT

06-09	Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million	BU
06-08	Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection	BU
06-02	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer, Founder and Former CEO of $1B NYSE Enterprise Which Delivered 8.5% Dividends to Shareholders	AQ
06-01	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders	BU
05-14	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026	BU

Aditxt, Inc. Stock

Stocks

ADTX

US0070258696

Biotechnology & Medical Research

Chart: Aditxt, Inc.

Latest news : Aditxt, Inc.

Analysts' recommendations: Aditxt, Inc.

Press Releases: Aditxt, Inc.

News in other languages: Aditxt, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aditxt, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+6.92%
1 week	-77.62%
Current month	-88.14%
1 month	-99.39%
3 months	-99.98%

1 week	0.01	0.05
1 month	0.01	2.36
Current year	0.01	117.84
1 year	0.01	117.84
3 years	0.01	117.84
5 years	0.01	117.84
10 years	0.01	117.84

Manager	Title	Age	Since
Jeffrey Busch CEO	Chief Executive Officer	68	2026-05-30
Shahrokh Shabahang PRN	Corporate Officer/Principal	63	2017-09-27
Thomas Farley DFI	Director of Finance/CFO	53	2021-09-26

Director	Title	Age	Since
Shahrokh Shabahang BRD	Director/Board Member	63	2017-09-27
Charles Nelson BRD	Director/Board Member	73	2023-11-02
Sylvia Hermina BRD	Director/Board Member	47	2024-10-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-07	HRT Financial LP	Other	Company	1,193,333	146.2559%
06-04	HRT Financial LP	Sell	Company	-735,462	90.1389%
06-03	HRT Financial LP	Other	Company	505,302	61.9303%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADITXT, INC.	+11.54%	-77.62%	-	-	10.61K
ARGENX SE	+1.03%	+2.30%	+54.92%	+111.78%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+0.98%	+2.67%	-13.81%	-17.63%	22.64B
INSMED INCORPORATED	+0.80%	+3.57%	+0.73%	+400.44%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+0.50%	+9.10%	-40.04%	15.3B
EXELIXIS, INC.	-0.79%	+0.75%	+27.08%	+178.13%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+2.25%	-8.08%	+28.86%	+107.85%	20.99B
Weighted average by Cap.	+1.65%	+1.60%	+33.73%	+100.53%

	2024	2025
Net sales	0.13 0.12 0.11 0.1 0.19 12.74 0.19 1.26 0.49 6.2 0.5 0.49 21.46	0 0 0 0 0 0.3 0 0.03 0.01 0.15 0.01 0.01 0.51
Net income	-34.45M -29.75M -27.42M -25.66M -48.09M -3.27B -48.84M -324M -126M -1.59B -129M -127M -5.52B	-41.71M -36.03M -33.2M -31.08M -58.24M -3.96B -59.14M -392M -153M -1.93B -157M -153M -6.68B
Net Debt	-	-